HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The BRCA2 R2645G variant increases DNA binding and induces hyper-recombination.

Abstract
BRCA2 tumor suppressor protein ensures genome integrity by mediating DNA repair via homologous recombination (HR). This function is executed in part by its canonical DNA binding domain located at the C-terminus (BRCA2CTD), the only folded domain of the protein. Most germline pathogenic missense variants are located in this highly conserved region which binds to single-stranded DNA (ssDNA) and to the acidic protein DSS1. These interactions are essential for the HR function of BRCA2. Here, we report that the variant R2645G, identified in breast cancer and located at the DSS1 interface, unexpectedly increases the ssDNA binding activity of BRCA2CTDin vitro. Human cells expressing this variant display a hyper-recombination phenotype, chromosomal instability in the form of chromatid gaps when exposed to DNA damage, and increased PARP inhibitor sensitivity. In mouse embryonic stem cells (mES), this variant alters viability and confers sensitivity to cisplatin and Mitomycin C. These results suggest that BRCA2 interaction with ssDNA needs to be tightly regulated to limit HR and prevent chromosomal instability and we propose that this control mechanism involves DSS1. Given that several missense variants located within this region have been identified in breast cancer patients, these findings might have clinical implications for carriers.
AuthorsLucia Alvaro-Aranda, Ambre Petitalot, Yasmina Djeghmoum, Davide Panigada, Jenny Kaur Singh, Åsa Ehlén, Domagoj Vugic, Charlotte Martin, Simona Miron, Aida Contreras-Perez, Naima Nhiri, Virginie Boucherit, Philippe Lafitte, Isaac Dumoulin, Etienne Rouleau, Eric Jacquet, Lidia Feliubadaló, Jesús Del Valle, Dominique Stoppa-Lyonnet, Sophie Zinn-Justin, Conxi Lázaro, Sandrine M Caputo, Aura Carreira
JournalNucleic acids research (Nucleic Acids Res) (Dec 24 2023) ISSN: 1362-4962 [Electronic] England
PMID38142462 (Publication Type: Journal Article)
Copyright© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: